Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy Combinations Transform Renal Cell Carcinoma Treatment
Patients with advanced renal cell carcinoma have new first-line therapy options.
FDA Approves Bavencio-Inlyta Combo for Advanced Renal Cell Carcinoma
Kristie L. Kahl
The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.
Yervoy Plus Opdivo Appears to be a Cost-Effective Treatment Option in Kidney Cancer
Kristie L. Kahl
With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.
Findings Confirm Exercise Benefit for Kidney Cancer Survivors
Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.
Immunotherapy Combinations Show Promise in Frontline Setting for Advanced Kidney Cancer
With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.
The Role of Mental Health in Cancer Outcomes
A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.
FDA Approves Keytruda in Combination with Inlyta for Frontline Renal Cell Carcinoma
The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.
Keytruda Combo Improves Survival in Advanced Renal Cell Carcinoma
Kristie L. Kahl
The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.
Expert Discusses Molecular Diagnosis of Renal Cell Carcinoma
There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.
Thanks to Immunotherapies, the Outlook for Patients with RCC is Changing
Mario Snozl, M.D.
An expert discusses the evolving treatments for renal cell carcinoma (RCC) over the last decade, as well as the future role of immunotherapies for patients with RCC.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: